BioInvent International AB
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, BioInvent International AB sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
BioInvent International AB: 5 sponsored US clinical trials, 3 recruiting.
BioInvent International AB sponsors 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Indolent B-Cell Non-Hodgkin Lymphoma, with 1 trials.
Upper-quartile sponsor footprint
BioInvent International AB sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
NCT04219254
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
NCT03571568
A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
NCT02756728
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma
NCT01025206
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
Therapeutic Areas
What is open in the BioInvent International AB pipeline
3 recruiting of 5 indexed (60% open); 1 completed (20%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Indolent B-Cell Non-Hodgkin Lymphoma (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
BioInvent International AB: open-pipeline peers nationwide
Peers matched on 5 registered trials and 60% open enrollment, not the therapeutic-area sidebar.
BioInvent International AB sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 60% open enrollment (± trial volume)
- Alaska Native Tribal Health Consortium · 60% recruiting · 5 trials
- Anwaar Saeed · 60% recruiting · 5 trials
- Autolus Limited · 60% recruiting · 5 trials
- Beam Therapeutics · 60% recruiting · 5 trials
Related
What to do with this BioInvent International AB page
5 registered trials is a research-attention snapshot, not an endorsement of BioInvent International AB or any single study.
- 3 of BioInvent International AB's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Indolent B-Cell Non-Hodgkin Lymphoma is the condition BioInvent International AB studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Indolent B-Cell Non-Hodgkin Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. BioInvent International AB pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.